

EXTENDED REPORT

Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis

M Aleksza*, A Szegedi*, P Antal-Szalmás, B Irinyi, L Gergely, A Ponyi, J Hunyadi, S Sipka, M Zeher, G Szegedi, K Dankó



Ann Rheum Dis 2005;64:1485–1489. doi: 10.1136/ard.2003.017715

See end of article for authors' affiliations

Correspondence to: Magdolna Aleksza, Blood bank of Zalaegerszeg, Zalaegerszeg 8900, Zarda str 4, Hungary; deb4@freemail.hu

Accepted 14 March 2005
Published Online First
13 April 2005

Objective: To investigate the intracellular and soluble cytokine levels and T cell subsets in peripheral blood of patients with active and inactive polymyositis and dermatomyositis.

Methods: The frequencies of T and B lymphocytes, T helper (Th), and T cytotoxic (Tc) cells and of interferon γ (IFN γ), interleukin (IL)4, and IL10 expression of CD4+ or CD8+ cells were determined by flow cytometry. The concentrations of soluble cytokines were measured with commercial enzyme linked immunosorbent assays.

Results: In active dermatomyositis there was a decreased percentage of T (CD3+) lymphocytes and Tc (CD8+) lymphocytes, decreased IFN γ expression of CD4+ and CD8+ cells, but an increase in B and IL4 producing CD4+ lymphocyte frequencies. These prominent changes disappeared in the inactive stage of the disease. In polymyositis no significant change in these lymphocyte subsets or in intracellular cytokine expression could be detected in either the active or the inactive form. The frequency of IL4+/IFN γ + Th cells was calculated and a significantly increased Th2/Th1 frequency was found in active dermatomyositis, and a decreased frequency in inactive dermatomyositis, compared with the control population.

Conclusions: There appears to be a difference between polymyositis and dermatomyositis in the level of peripheral blood lymphocytes and their intracellular cytokine content. These findings provide further evidence for a difference in the pathogenesis of polymyositis and dermatomyositis.

Polymyositis and dermatomyositis are idiopathic inflammatory myopathies of unknown origin, although immunological mechanisms may be involved in their pathogenesis.^{1,2} There are data suggesting that these two diseases may be pathogenetically similar,³⁻⁷ while other reports provide evidence that their origin essentially different.

In polymyositis T cell mediated cytotoxicity rather than humoral immunity may be the main effector mechanism, as immunohistochemical studies on muscle biopsies have shown that most of the T cells in the endomysium surrounding and invading single myofibres are of CD8+ type.^{1,8,9} Cytotoxic granules of CD8+ T cells release perforin and serine esterases, which contribute to muscle cell death. Oligoclonal expansions of CD8+ T cells have been found in the blood and within muscle biopsies in polymyositis, but not in dermatomyositis.¹⁰⁻¹² On the other hand in dermatomyositis humorally mediated damage to muscle blood vessels seems to be more important in the pathogenesis. Inflammatory infiltrates mainly consist of activated B cells and are concentrated in the interstitial and perivascular areas.^{13,14} Deposition of the membrane attack complex of complement is often seen in the muscle vessels in dermatomyositis, and the vessel injury appears to be complement mediated.¹⁵ The pattern of perifascicular atrophy of muscle fibres is characteristic and attributed to ischaemic effects.

Cytokines have important functions in inflammatory processes and are likely to participate in the pathogenesis of idiopathic inflammatory myopathies. The role of cytokines in these diseases is, however, poorly understood. Cytokine studies have shown raised serum interleukin 1 (IL1) receptor antagonist in patients with active polymyositis and dermatomyositis, but low levels of tumour necrosis factor α and IL1 β .¹⁶ Immunohistochemical investigations of cytokines showed that cytokine expression in muscle tissue is dominated by IL1 α , IL1 β , and transforming growth factor (TGF) β 1-3.¹⁷ Local release of T cell derived cytokines is not

remarkable in inflammatory myopathies. To detect the cytokine secretion of peripheral blood mononuclear cells the ELISpot assay was used previously in one study, but no published data are available on intracellular cytokine production measured by flow cytometry in polymyositis and dermatomyositis.⁹

To gain better insight into the pathogenesis of these myopathies we investigated cytokine levels in the sera of patients with polymyositis and dermatomyositis. We also used a flow cytometric assay to detect the peripheral blood lymphocyte subsets and the intracellular cytokines produced in these cells. An additional aim was to investigate the proportion of T helper (Th) 1 (CD4+/IFN γ +), Th2 (CD4+/IL4+), T cytotoxic (Tc) 1 (CD8+/IFN γ +), and Tc2 (CD8+/IL4+) lymphocytes in polymyositis and dermatomyositis. Patients were tested in both the active and the inactive states of the disease.

METHODS

Patients and controls

Individuals enrolled in this study were patients suffering from polymyositis (37 women, 13 men; mean (SD) age 45.9 (13.7) years, range 20 to 69) or dermatomyositis (33 women, 16 men; age 46.9 (13.5) years, range 13 to 73) followed up in our outpatient department. Their diagnosis was defined on the basis of the international criteria of Boham and Peter¹⁸ and the disease activity assessment was based on the clinical symptoms, muscle strength, and laboratory indices (serum creatinine kinase (CK) and lactate dehydrogenase (LDH) activity, table 1). The number of patients with active polymyositis was 13 (eight women, five men; mean (SD) age, 43.1 (14.1) years), while 37 patients were in the inactive stage of the disease (29 women, eight men; age 46.9 (13.6) years) at the initiation of the study. The number of patients with active dermatomyositis was 29 (18 women, 11 men; age

Table 1 Autoantibody positivities in active and inactive polymyositis (aPM and iPM) and dermatomyositis (aDM and iDM)

	Active disease	Inactive disease	p Value
Dermatomyositis			
n	29	20	
Age (years)	46.5 (13.5)	47.4 (13.6)	NS
Age range (years)	13 to 70	24 to 73	
Male/female	11/18	5/15	
CK (U/l)	1371 (2254)	74 (35)	p=0.01
LDH (U/l)	764 (527)	362 (84)	p<0.01
Anti-ENA positivity	4	2	NS
Anti-Jo-1 positivity	1	0	NS
ANF HEp-2 positivity	4	9	NS
Polymyositis			
n	13	37	
Age (years)	43.1 (14.1)	46.9 (13.6)	NS
Age range (years)	20 to 69	18–69	
Male/female	5/8	8/29	
CK	1000 (1873)	169 (235)	p=0.01
LDH	1028 (1430)	394 (143)	p=0.01
Anti-ENA positivity	5	4	p=0.03
Anti-Jo-1 positivity	4	2	p=0.01
ANF HEp-2 positivity	3	4	NS

Values are mean (SD) or n unless specified. Significant p values in bold. ANF, antinuclear factor; CK, creatine kinase; ENA, extractable nuclear antigen; LDH, lactate dehydrogenase.

46.5 (13.5) years), while 20 (15 women, five men; age 47.4 (13.6) years) had inactive disease. The healthy controls were members of the clinical staff (24 women, eight men; age 30.9 (9.1) years, range 20 to 56). Informed consent was obtained from each control and patient.

Phenotypic characterisation of whole blood lymphocytes

Heparinised whole blood was incubated in the presence of saturating concentrations of directly labelled monoclonal antibodies (mAb) for 30 minutes at room temperature in the dark. The erythrocytes were lysed and the samples were fixed according to the Coulter QPREP protocol (Coulter, Hialeah, Florida, USA). The monoclonal antibodies applied were: FITC labelled anti-CD3 and FITC labelled CD8 (Sigma, St Louis, Missouri, USA); PE labelled anti-CD4, PerCP labelled anti-CD19, and FITC labelled anti-CD3/PE labelled anti-HLA-DR (Immunotech, Nyon, Switzerland); and CyChrome labelled anti-CD69 (Pharmingen, BD Biosciences, San Jose, California, USA). The samples were measured using a Coulter EPICS XL flow cytometer and analysed by System II 3.0 software. Lymphocytes were gated on their forward and side scatter properties and the proportions of B cells, Th cells, Tc cells, and resting and activated T cells were determined

within the defined lymphocyte gate, based on their antigen positivity.

Measurement of intracellular cytokine expression of Th and Tc lymphocytes in whole blood

As resting lymphocytes do not contain substantial quantities of cytokines, we stimulated T cells in whole blood by phorbol myristate acetate (PMA, 25 ng/ml, Sigma) and ionomycin (1 µg/ml, Sigma) for four hours at 37°C. Activation was done in the presence of Brefeldin-A (Sigma, 10 µg/ml) which inhibits intracellular transport so that cytokines produced during the activation will be retained inside the cells. After the stimulation of the Th and Tc cells, samples were marked by quantum red labelled anti-CD4 or anti-CD8 (Sigma) mAb for 30 minutes at room temperature in the dark. Then FACS lysing solution (Becton Dickinson, San Jose, California, USA) was used for 10 minutes to lyse the erythrocytes and fix the whole blood leucocytes. After a washing step, the plasma membrane of the cells was permeabilised by the FACS permeabilising solution (Becton Dickinson) for another 10 minutes. The fixed and permeabilised leucocytes were labelled by anti-IFNγ-FITC and anti-IL4-PE (Becton Dickinson) or anti-IL10-PE mAb (Caltag, Burlingame, California, USA) for 30 minutes at room temperature in the dark. The samples were measured by a Coulter EPICS XL flow cytometer. Data from about 5000 Th or Tc lymphocytes were collected in each sample. These cells were gated, based on their side scatter/forward scatter and CD4 or CD8 positivity. The proportion of IFNγ, IL4, and IL10 positive cells was determined among the CD4+ and CD8+ T cells.

Measurement of autoantibodies

Anti-ENA and anti-Jo-1 (Hycor) antibodies were detected by enzyme linked immunosorbent assay kits (ELISA). We detected antinuclear factor (ANF) antibodies in HEp-2 cells by an indirect immunofluorescence technique.

Measurement of serum cytokine concentrations by ELISA

We measured the levels of circulating cytokines (IFNγ, IL4, and IL10) in the serum of patients and controls. Serum samples were collected on every experimental day and were stored at -80°C until testing with commercial cytokine ELISAs (OptEIA™ system, Pharmingen) according to the manufacturer's instructions.

Statistical analysis

The differences between the healthy controls and the patients with polymyositis or dermatomyositis were calculated by Student's unpaired *t* test. Correlations between variables were assessed by Pearson regression using the Statistica for

Table 2 T cell subpopulations and activated T cells in peripheral blood in controls and in patients with active and inactive dermatomyositis

	Patients with aDM (n = 29)	Patients with iDM (n = 20)	Controls (n = 32)	p Values		
				aDM v control	iDM v control	aDM v iDM
CD3+ cells (%)	64.8 (11.4)	71.8 (7.1)	70.3 (7.2)	p<0.01	NS	p<0.05
CD4+ cells (%)	48.3 (10.1)	49.2 (10.9)	45.2 (7.6)	NS	NS	NS
CD8+ cells (%)	15.1 (7.1)	20.9 (9.3)	19.6 (5.9)	p<0.01	NS	p<0.05
CD19+ cells (%)	16.8 (10.7)	11.1 (4.3)	11.7 (4.1)	p<0.01	NS	p<0.05
CD3+ and HLADR+ cells (%)	6.4 (4.1)	7.4 (5.7)	3.0 (2.3)	p<0.01	p<0.01	NS
CD3+ and CD69+ cells (%)	1.4 (0.9)	1.3 (0.7)	1.0 (0.8)	NS	NS	NS

Values are mean (SD). Significant p values in bold.

The samples were measured by flow cytometry and lymphocytes were identified on the basis of their scatter properties. aDM, active dermatomyositis; iDM, inactive dermatomyositis.

Table 3 T cell subpopulations and activated T cells of peripheral blood in controls and in patients with active and inactive polymyositis

	Patients with aPM (n=13)	Patients with iPM (n=37)	Controls (n=32)	p Values		
				aPM v control	iPM v control	aPM v iPM
CD3+ cells (%)	66.2 (9.4)	70.4 (8.1)	70.3 (7.2)	NS	NS	NS
CD4+ cells (%)	42.3 (12.4)	46.9 (9.8)	45.2 (7.6)	NS	NS	NS
CD8+ cells (%)	21.6 (10.2)	20.6 (6.4)	19.6 (5.9)	NS	NS	NS
CD19+ cells (%)	13.8 (7.4)	10.9 (7.4)	11.7 (4.1)	NS	NS	NS
CD3+ and HLADR+ cells (%)	13.6 (14.3)	9.4 (7.8)	3.0 (2.3)	p<0.01	p<0.01	NS
CD3+ and CD69+ cells (%)	1.5 (1.0)	1.2 (0.9)	1.0 (0.8)	NS	NS	NS

Values are mean (SD).
The samples were measured by flow cytometry and lymphocytes were identified on the basis of their scatter properties.
aPM, active polymyositis; iPM, inactive polymyositis.

Windows software. A significant difference was defined as $p \leq 0.05$.

RESULTS

Distribution of lymphocyte subpopulations in whole blood of patients suffering from active or inactive dermatomyositis or polymyositis

We found a major difference in lymphocyte phenotypisation only in the case of dermatomyositis. Patients in the active state of this disorder had a significantly decreased percentage of CD3+ cells ($p < 0.01$) and CD8+ cells ($p < 0.01$), and an increased percentage of CD19+ cells ($p < 0.01$) compared with healthy controls and with the inactive disease state (table 2).

Beside the regular lymphocyte subtypes we also determined the percentage of activated T cells in our samples based on the HLA-DR or CD69 expression or CD3 positive T cells. Independent of the activity of the disorders we observed significantly increased frequencies only in the CD3+/HLA- DR+ cells both in dermatomyositis and polymyositis compared with the controls (control v active dermatomyositis, $p < 0.01$; v inactive dermatomyositis, $p < 0.01$; v active polymyositis, $p < 0.01$; v inactive polymyositis, $p < 0.01$; tables 2 and 3).

Intracellular cytokine expression in peripheral lymphocytes of patients with dermatomyositis

The frequency of IFN γ + Th1 cells was significantly lower ($p < 0.01$) in active dermatomyositis than in controls or in patients with inactive disease (active disease, 10.6 (7.1)%; inactive disease, 22.7 (10.0); control, 22.1 (10.0)%). The frequency of IFN γ + Tc1 lymphocytes was also significantly decreased in active dermatomyositis compared with the controls (active disease, 24.4 (16.5)% v 43.4 (8.5)% in controls, $p < 0.01$) (fig 1A).

The percentage of IL4+ Th2 cells was markedly increased in active dermatomyositis and decreased in inactive dermatomyositis compared with the controls (active disease, 1.01 (0.66)%; inactive disease, 0.33 (0.3)%; controls, 0.62 (0.54)%), and the difference between the values of the active and inactive states was significant ($p = 0.05$) (fig 1B). In CD8+ cells we could not detect any measurable change in intracellular IL4 expression.

The frequencies of IL10-containing CD4+ and CD8+ T cells were higher in both active and inactive dermatomyositis, but the differences were significant only for inactive dermatomyositis (CD4+/IL10+: control, 2.8 (4.1)%; inactive dermatomyositis, 6.5 (5.6)%, $p = 0.04$; CD8+/IL10+: control, 3.7 (4.3)%, inactive disease, 8.8 (6.7)%, $p = 0.01$).




Figure 1 Expression of intracellular interferon γ (IFN γ) (panel A) and interleukin 4 (IL4) (panel B) in stimulated peripheral T helper (Th) and T cytotoxic (Tc) cells of patients with dermatomyositis (DM) and polymyositis (PM). The samples were measured by flow cytometry, and lymphocytes were identified on their scatter properties and CD4/CD8 positivities.




Figure 2 Calculated Th2/Th1 frequency (Th2: IL4+/CD4+; Th1: IFN γ +/CD4+) in active and inactive polymyositis (PM) and dermatomyositis (DM). IFN, interferon; IL, interleukin; Th, T helper cell.

The calculated Th/Th2 frequencies were significantly lower in active dermatomyositis and higher in inactive disease than in the controls (fig 2).

Intracellular cytokine expression in peripheral lymphocytes of patients with polymyositis

The frequency of IFN γ and IL4 positive Th and Tc cells did not differ significantly compared with the healthy controls (fig 1A and 1B). Though the percentages of IL10 positive Th and Tc lymphocytes—independently of disease activity—were higher in the patients than in the controls, these differences were not significant (data are not shown).

Levels of soluble cytokines in serum of patients with dermatomyositis and polymyositis

Besides the intracellular levels of cytokines we determined the cytokine patterns in the sera of patients with polymyositis and dermatomyositis using commercially available ELISA systems. Probably because of the high degree of individual variation and the low cytokine levels, hardly any significant differences could be observed between patients and controls.

In the case of dermatomyositis and polymyositis, independently of disease activity the concentrations of IFN γ , IL4, and IL10 were non-significantly raised compared with the controls (data not shown).

DISCUSSION

This study was undertaken to gain further insight into the pathogenesis of idiopathic inflammatory myopathies. The most important finding in our work was the pronounced difference in the frequency of the peripheral blood lymphocyte subsets and also in the intracellular cytokine content of these cells between patients with active and inactive polymyositis or dermatomyositis.

In active dermatomyositis we detected not only a significantly decreased CD3+ and CD8+ T lymphocyte frequency but also an increased CD19+ B lymphocyte frequency. The percentage of activated T cells (CD3+/HLADR+) was significantly increased in both dermatomyositis and polymyositis, but in active polymyositis no other alterations in the frequency of peripheral blood lymphocytes were detected. In inactive dermatomyositis these deviations in the lymphocyte subsets disappeared and the frequencies of the CD3+, CD8+, and CD19+ cells became normal, while that of the activated T lymphocytes was persistently high. In inactive polymyositis the number of the activated T cells remained increased as well, without any other alteration in comparison with the control population. Iannone *et al* also studied the peripheral blood mononuclear cell subsets in patients with polymyositis and dermatomyositis and, in agreement with our findings, they detected a normal percentage of total CD3+/CD8+ cells in polymyositis, while in dermatomyositis they found a significantly lower proportion CD3+/CD8+ cells

than in controls.¹⁹ They also showed that the number of activated T cells was increased in both polymyositis and dermatomyositis, although for the detection of activated T cells they used the CD3+/CD25+ double positive staining, while we used the CD3+/HLADR+ double positive staining. Concerning the frequency of B lymphocytes, our results also show good correlation with published data. In adults with idiopathic inflammatory myopathies, an increase in the proportion of B cells in patients with dermatomyositis has been reported, and an increased frequency of B cells was also detected in new onset, untreated patients with juvenile dermatomyositis.^{20, 21} Eisenstein and colleagues observed that the increased percentage of peripheral blood B cells normalised in children with improving juvenile dermatomyositis, and this change correlated with changes in disease activity.²²

The intracellular cytokine content of the peripheral blood lymphocytes also showed striking differences between patients with dermatomyositis and polymyositis. In active dermatomyositis an altered Th1 and Tc1 lymphocyte frequency was observed, as the percentage of IFN γ containing CD4+ and CD8+ T lymphocytes was significantly decreased compared with the control population. This prominent change disappeared in the inactive disease state. On the other hand in active dermatomyositis a marked increase in the frequency of CD4+/IL4+ cells was observed, while in inactive dermatomyositis these changes disappeared and we detected a decrease in the IL4+/CD4+ cell number compared with the controls. The frequency of IL4 producing cytotoxic T lymphocytes was not different between patients and controls.

Studies of lupus-prone mice and humans indicate that immune abnormalities may be more closely associated with changes in the frequency of type 2:type 1 cytokine secreting cells, than with changes in the absolute number of cells producing any single cytokine.²³ For this reason we calculated the frequency of IL4/IFN γ secreting cells. While in active dermatomyositis a significantly increased Th2/Th1 frequency was detected, in inactive disease a decrease in Th2/Th1 frequency was found compared with the control population. Such alterations were not detected in polymyositis.

We also studied the number of IL10 producing Th and Tc cells. In dermatomyositis and polymyositis we observed an increase in the percentage of IL10 secreting cells, although this was significant only in inactive dermatomyositis. The reason for this discrepancy between the numbers of IL4 and IL10 producing T cells may be that IL10 is not a pure type 2 cytokine. IL10 is produced by both Th1 and Th2 lymphocytes and is an important immunoregulatory cytokine. IL10 has the ability to downregulate several major functions of Th1 cells and macrophages and can also control the Th2 mediated inflammatory processes. We detected higher levels of IL10 secreting T cells in dermatomyositis than in polymyositis, but the difference was not so marked between the two diseases as was observed in the number of IL4+ or IFN γ + cells.

Lundberg and colleagues carried out indirect immunohistochemistry studies of muscle tissue sections with a panel of 16 different cytokine specific monoclonal antibodies in 15 untreated patients with polymyositis, dermatomyositis, and inclusion body myositis.¹⁷ They concluded that the cytokine expression in muscle tissue of patients with inflammatory myopathy is dominated by IL1 α , IL1 β , and TGF β 1–3. INF γ staining was detected in six of 15 patients, IL10 was observed in five patients, but IL4 was absent in all patients and the authors assumed that local release of T cell derived cytokines may not be a requirement for tissue injury in the inflammatory myopathies. There did not appear to be a qualitative difference in cytokine expression patterns in polymyositis, dermatomyositis, or inclusion body myositis. These results do not contradict our findings, as in autoimmune diseases the cytokine content of lymphocytes is not necessarily the same in the peripheral

blood and in the affected tissues. It is usually accepted that thyroid autoimmunity is an autoimmune disease mediated by Th1 cells, but recent results show a major difference in the balance of Th1 and Th2 cytokines secreted by cultures of thyroid and peripheral blood lymphocytes.²⁴

To study the cytokine content of the peripheral blood mononuclear cells Hagiwara and colleagues used the ELISpot technique and showed that in dermatomyositis patients with active disease had significantly fewer peripheral blood mononuclear cells spontaneously secreting IFN γ than normal controls.⁹ Moreover they showed that subjects with active dermatomyositis had fewer cells secreting IFN γ than patients with inactive disease. Their results are consistent with our findings in the case of dermatomyositis, as they also detected an altered type 1 cytokine pattern. They did not investigate the number of IL4 containing cells but detected the frequency IL6 producing cells. They showed a modest but statistically significant increase in the number of cells secreting IL6 in patients with dermatomyositis. They also found an altered type 2/type 1 cytokine frequency in dermatomyositis, similar to our results, but they counted this frequency from the IL10/IFN γ rate. Instead of IL10 we used IL4 in our calculation, as type 1 T cells also produce IL10. In the case of polymyositis our results are in contrast to the findings of Hagiwara and colleagues, as they found that the number of cells producing IFN γ was also decreased in polymyositis, and patients with polymyositis showed an increase in IL10 (type 2) production and a decrease in IFN γ (type 1) production. On the other hand, they also found differences between the cytokine production of the peripheral blood mononuclear cells of patients with dermatomyositis and polymyositis. They showed that dermatomyositis can be distinguished from the other myopathies by the significantly reduced frequency of IL2 (type 1) producing, and the increased frequency of IL6 (type 2) producing, peripheral blood mononuclear cells when compared with other myopathies and normal controls. The reason for the partial discrepancy between their results and ours may be that we used different methods for cytokine determinations.

Serum levels of cytokines were not significantly different between dermatomyositis, polymyositis, and controls and did not correlate with results of the intracellular cytokine staining. This is not surprising, as serum cytokine levels cannot be used to determine the number of cells secreting type 1 or type 2 cytokines in vivo owing to their short serum half life, rapid uptake, utilisation, presence of blocking factors in the serum, and other sources of production.²⁵⁻²⁷

Kikuchi and colleagues showed that the percentage of activated B cells (RP105) in the peripheral blood of patients with polymyositis was low; in contrast, patients with dermatomyositis showed an increase in the RP105 negative B cell populations.⁵ They concluded that B cell activation in dermatomyositis may be pathogenically different from that in polymyositis, and we believe that this B cell activation may be the result of the increased Th2:Th1 frequency observed in our study.

ACKNOWLEDGEMENTS

This work was supported by the National Scientific Research Program of the Welfare Ministry of Hungary (OTKA T037430 and OTKA T030336)

Authors' affiliations

M Aleksza*, **I Gergely**, **A Panyi**, **S Sipka**, **M Zeher**, **G Szegedi**, **K Dankó**, Third Department of Internal Medicine, University of Debrecen, Medical and Health Science Centre, Debrecen, Hungary
A Szegedi*, **B Irinyi**, **J Hunyadi**, Department of Dermatology, University of Debrecen, Medical and Health Science Centre

P Antal-Szalmás, Department of Clinical Biochemistry and Molecular Pathology, University of Debrecen, Medical and Health Science Centre

*Magdolna Aleksza and Andrea Szegedi participated equally in this work.

REFERENCES

- 1 **Targoff IN**. Humoral immunity in polymyositis/dermatomyositis. *J Invest Derm* 1993;(suppl 1):116S-23S.
- 2 **Targoff IN**. Immunologic aspects of myositis. *Curr Opin Rheumatol* 1989;1:432-42.
- 3 **Nyberg P**, Wikman AL, Nennesmo I, Lundberg I. Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. *J Rheumatol* 2000;27:940-8.
- 4 **Sugiura T**, Kawaguchi Y, Harigai M, Takagi K, Ohta S, Fukasawa C, et al. Increased CD40 expression on muscle cells of polymyositis and dermatomyositis; role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. *J Immunol* 2000;164:6593-600.
- 5 **Kikuchi Y**, Koarada S, Tada Y, Ushiyama O, Morito F, Suzuki N, et al. Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells. *Ann Rheum Dis* 2001;60:1137-40.
- 6 **Urbano-Marquez A**, Casademont J, Grau JM. Polymyositis/dermatomyositis; the current position. *Ann Rheum Dis* 1991;50:191-5.
- 7 **Brouwer R**, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, et al. Autoantibody profiles in the sera of European patients with myositis. *Ann Rheum Dis* 2001;60:116-23.
- 8 **Arahata K**, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. Cell-mediated cytotoxicity and muscle fiber necrosis. *Ann Neurol* 1988;23:168-73.
- 9 **Hagiwara E**, Adams EM, Plotz PH, Klinman DM. Abnormal numbers of cytokine producing cells in patients with polymyositis and dermatomyositis. *Clin Exp Rheumatol* 1996;14:485-91.
- 10 **Benveniste O**, Cherin P, Maisonobe T, Merat R, Chosidow O, Mouthon L, et al. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. *J Immunol* 2001;167:3521-9.
- 11 **O'Hanlon TP**, Dalakas MC, Plotz PH, Miller FW. Predominant TCR- $\alpha\beta$ variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. *J Immunol* 1994;152:2569-76.
- 12 **Bender A**, Ernst N, Iglesias A, Dornmair K, Wekerle H, Hohlfield R. T cell receptor repertoire in polymyositis; clonal expansion of autoaggressive CD8+ T cells. *J Exp Med* 1995;181:1863-8.
- 13 **Hohlfield R**, Goebels N, Engel AG. Cellular mechanism in inflammatory myopathies. *Baillieres Clin Neurol* 1993;2:617-35.
- 14 **Engel AG**, Arahata K. Mononuclear cells in myopathies; quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. *Hum Pathol* 1986;17:704-21.
- 15 **Kissel JT**, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. *N Engl J Med* 1982;286:314-34.
- 16 **Gabay C**, Gay-Croisier F, Roux-Lombard P, Meyer O, Mainetti C, Guerne PA, et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: a biologic marker of disease activity with a possible role in the lack of acute-phase protein response. *Arthritis Rheum* 1994;37:1744-51.
- 17 **Lundberg I**, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. *Arthritis Rheum* 1997;40:865-74.
- 18 **Bohan A**, Peter JB. Polymyositis and dermatomyositis. *N Engl J Med* 1975;292:344-7.
- 19 **Iannone F**, Cauli A, Yanni G, Kingsley GH, Isenberg DA, Corrigan V, et al. T-lymphocyte immunophenotyping in polymyositis and dermatomyositis. *Br J Rheumatol* 1996;35:839-45.
- 20 **Miller FW**, Love LA, Barbieri SA, Balow JE, Plotz PH. Lymphocyte activation markers in idiopathic myositis. Change with disease activity and differences among clinical and autoantibody subgroups. *Clin Exp Immunol* 1990;81:373-9.
- 21 **O'Gorman MRG**, Corrochano V, Rolek J, Donovan M, Pachman LM. Flow cytometric analysis of the lymphocyte subsets in patients with untreated, active juvenile dermatomyositis. *Clin Diagn Lab Immunol* 1995;2:205-8.
- 22 **Eisenstein DM**, O'Gorman MRG, Pachman LM. Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. *J Rheumatol* 1997;24:1830-2.
- 23 **Hagiwara E**, Gourley MF, Lee S, Klinman DM. Disease severity in patients with SLE correlates with an increased frequency of IL-10. IFN- γ secreting cells in the peripheral blood. *Arthritis Rheum* 1996;39:379-85.
- 24 **Guo J**, Rapoport B, McLachlan SM. Balance of Th1/Th2 cytokines in thyroid autoantibody synthesis in vitro. *Autoimmunity* 1999;30:1-9.
- 25 **Oliver JC**, Bland LA, Oettinger CW, Arduino MI, McAllister SK, Aguerro SM, et al. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. *Lymphokine Cytokine Res* 1993;12:115-20.
- 26 **Shirai A**, Holmes K, Klinman DM. Detection and quantitation of cells secreting IL-6 under physiological conditions in BALB/c mice. *J Immunol* 1993;150:793-9.
- 27 **Waage A**, Brandtzaeg P, Halsensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. *J Exp Med* 1989;169:333-8.